2-Hexanone Potentiation of [14C]chloroform Hepatotoxicity: Covalent Interaction of a Reactive Intermediate with Rat Liver Phospholipid
-
1984/05/01
-
Details
-
Personal Author:
-
Description:Rats were treated with [14C]chloroform (14CHCl3) in corn oil (CO) or corn oil alone 18 hr following pretreatment with 2-hexanone (2-HX) in corn oil or corn oil alone. Livers were removed, homogenized 1, 2, and 6 hr post-14CHCl3 administration, and glutathione (GSH) content, irreversible binding of 14CHCl3-derived radiolabel, and phospholipid composition were determined. The combination of 2-HX + CHCl3 reduced GSH content to 21% of control (CO + CO) 1 hr after CHCl3 administration. No significant rebound of GSH was observed 24 hr post-CHCl3 administration. In contrast, GSH was not altered by administration of CHCl3 to CO-pretreated rats. Although 14CHCl3-derived radiolabel was irreversibly bound to hepatic macromolecules of both CO- and 2-HX-pretreated rats, total irreversibly bound 14C was significantly enhanced in 2-HX-pretreated rats at all time points. The latter observation was consistent with the decrease in GSH of 2-HX-pretreated rats. Total 14C binding in 2-HX-pretreated rats reached a plateau 2 hr post-14CHCl3 administration and was distributed 52% in protein, 41% in lipid, and 7% in acid soluble fractions 6 hr post-14CHCl3 administration. 2-HX enhanced 14C binding to protein and lipid at each time point. Radiolabel was not detected in neutral lipids of control or 2-hexanone-treated animals, but was enhanced 33-fold in phospholipids of 2-hexanone-treated animals. Phospholipid fatty acid methyl ester derivatives did not contain 14C indicating the radiolabel was most likely associated with phospholipid polar head groups. Two dimensional thin layer chromatographic analysis of phospholipid from treated animals demonstrated that 87% of the total radiolabel was associated with a specific phospholipid (14C-PL) which had a 1:1 molar ratio of phosphate to 14C. The latter indicates that the 14C-PL was a monophospholipid derivative of 14CHCl3 reactive intermediate, generally thought to be phosgene. Concurrent decrease in phosphatidylethanolamine content from 23% of total phospholipid to 7%, accumulation of 14C-PL to 2.6% of total phospholipid, and increase in lysophosphatidylethanolamine from 1 to 7% of total phospholipid durkng 2-hexanone + 14CHCl3 treatment indicated that the amine moiety of phosphatidylethanolamine polar head groups was the probable target of phosgene-lipid interaction, and that a degradative pathway existed which removed the abnormal phospholipid from hepatic membranes. No phospholipid other than phosphatidylethanolamine was depleted. During model studies, 12% phosgene in toluene was reacted with liver phosphatidylethanolamine for 6 hr at 37 degrees C. Two reaction products were formed, further substantiating that phosphatidylethanolamine (PE) may react with [14C]phosgene in liver. Although the data presented here are insufficient to conclude that the depletion of PE is a major mechanism in CHCl3 hepatotoxicity, documented studies in which altered phospholipid composition modified cellular function suggest the possibility that PE depletion may contribute to phosgene-induced liver injury. [Description provided by NIOSH]
-
Subjects:
-
Keywords:
-
ISSN:0041-008X
-
Document Type:
-
Funding:
-
Genre:
-
Place as Subject:
-
CIO:
-
Topic:
-
Location:
-
Pages in Document:478-491
-
Volume:73
-
Issue:3
-
NIOSHTIC Number:nn:20060627
-
Citation:Toxicol Appl Pharmacol 1984 May; 73(3):478-491
-
CAS Registry Number:
-
Federal Fiscal Year:1984
-
Peer Reviewed:True
-
Source Full Name:Toxicology and Applied Pharmacology
-
Collection(s):
-
Main Document Checksum:urn:sha-512:5adc7d4f5dc0413b45abbac7684d41397533a85ffa3847ed92b3cc01b32413556fd35ffbb8c551fcb0da59c50dcd003d97e9cf4cdbd16dd7a3bc3e6644b66331
-
Download URL:
-
File Type:
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like